跳至主要内容
临床试验/ACTRN12622001080718
ACTRN12622001080718尚未招募未知

A Prospective Cohort Study assessing the feasibility, efficacy and safety of Cardiac Stereotactic Body Radiotherapy (SBRT) in patients with Ventricular Tachycardia (VT)

Metro South Hospital0 个研究点目标入组 10 人开始时间: 2022年8月4日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Documented sustained ventricular tachycardia (VT) with at least 3 episodes of VT in 12 months prior to enrollment
  • Require at least 1 anti-arrhythmic medication
  • Failed at least 1 invasive catheter ablation procedure, or have contraindications to invasive catheter ablation
  • Assessed as able to tolerate radiotherapy planning, immobilisation and treatment as deemed by the radiation oncologist
  • Willing and able to provide informed consent

排除标准

  • Previous radiotherapy to the chest with any radiation dose to the heart
  • Advanced heart failure (NYHA Class IV)
  • High-volume myocardial scar substrate to such an extent that treatment with Stereotactic Body Radiotherapy (SBRT) is deemed unsafe by the radiation oncologist
  • Ventricular Tachycardia (VT) deemed not to be related to a definable myocardial scar
  • Competing comorbidities (unrelated to VT) which limit life expectancy to less than 6 months.
  • Must not be pregnant and/or breastfeeding if female; must have a negative pregnancy test within 7 days of study enrollment.
  • Implantable Cardiac Defibrillator (ICD) implanted less than 6 weeks prior
  • Renal failure or allergy precluding administration of Intravenous (IV) gadolinium
  • Computer Tomography (CT) IV contrast allergy
  • Any concurrent anti-neoplastic therapy

研究者

发起方
Metro South Hospital

相似试验